ADC Therapeutics (ADCT) Capital Expenditures Growth (1y) (2021 - 2026)
ADC Therapeutics (ADCT) Capital Expenditures Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | ADC Therapeutics | 174.95 Mn | -56.06 Mn | 17.38 Mn | -87.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -87.88% |
| Mar 31, 2025 | -50.28% |
| Dec 31, 2024 | -72.48% |
| Sep 30, 2024 | -67.32% |
| Jun 30, 2024 | -97.52% |
| Mar 31, 2024 | -47.74% |
| Dec 31, 2023 | 52.80% |
| Sep 30, 2023 | 240.72% |
| Jun 30, 2023 | 2,324.00% |
| Mar 31, 2023 | 343.67% |
| Dec 31, 2022 | -49.05% |
| Sep 30, 2022 | -86.19% |
| Jun 30, 2022 | -94.73% |
| Mar 31, 2022 | -65.14% |
| Dec 31, 2021 | 141.38% |
| Sep 30, 2021 | 250.37% |
| Jun 30, 2021 | 658.40% |
| Mar 31, 2021 | 550.50% |